Literature DB >> 20477920

Psoriasis: is the impairment to a patient's life cumulative?

A B Kimball1, U Gieler, D Linder, F Sampogna, R B Warren, M Augustin.   

Abstract

Psoriasis is associated with significant physical and psychological burden affecting all facets of a patient's life--relationships, social activities, work and emotional wellbeing. The cumulative effect of this disability may be self-perpetuating social disconnection and failure to achieve a 'full life potential' in some patients. Health-related quality of life studies have quantified the burden of psoriasis providing predominantly cross-sectional data and point-in-time images of patients' lives rather than assessing the possible cumulative disability over a patient's lifetime. However, social and economic outcomes indicate there are likely negative impacts that accumulate over time. To capture the cumulative effect of psoriasis and its associated co-morbidities and stigma over a patient's life course, we propose the concept of 'Cumulative Life Course Impairment' (CLCI). CLCI results from an interaction between (A) the burden of stigmatization, and physical and psychological co-morbidities and (B) coping strategies and external factors. Several key aspects of the CLCI concept are supported by data similar to that used in health-related quality of life assessments. Future research should focus on (i) establishing key components of CLCI and determining the mechanisms of impairment through longitudinal or retrospective case-control studies, and (ii) assessing factors that put patients at increased risk of developing CLCI. In the future, this concept may lead to a better understanding of the overall impact of psoriasis, help identify more vulnerable patients, and facilitate more appropriate treatment decisions or earlier referrals. To our knowledge, this is a first attempt to apply and develop concepts from 'Life Course Epidemiology' to psoriasis research.

Entities:  

Mesh:

Year:  2010        PMID: 20477920     DOI: 10.1111/j.1468-3083.2010.03705.x

Source DB:  PubMed          Journal:  J Eur Acad Dermatol Venereol        ISSN: 0926-9959            Impact factor:   6.166


  39 in total

Review 1.  Progress to Date in Advancing Stratified Medicine in Psoriasis.

Authors:  Claire Reid; Lis Cordingley; Richard B Warren; Christopher E M Griffiths
Journal:  Am J Clin Dermatol       Date:  2020-10       Impact factor: 7.403

2.  Transitional care in inflammatory bowel disease.

Authors:  Jessica R Philpott
Journal:  Gastroenterol Hepatol (N Y)       Date:  2011-01

Review 3.  Unmet Needs in the Field of Psoriasis: Pathogenesis and Treatment.

Authors:  Wolf-Henning Boehncke; Nicolo Costantino Brembilla
Journal:  Clin Rev Allergy Immunol       Date:  2018-12       Impact factor: 8.667

Review 4.  Chronic diseases influence major life changing decisions: a new domain in quality of life research.

Authors:  Zu Bhatti; Ms Salek; Ay Finlay
Journal:  J R Soc Med       Date:  2011-06       Impact factor: 5.344

Review 5.  The burden of moderate to severe psoriasis: an overview.

Authors:  Giovanna Raho; Daniela Mihajlova Koleva; Livio Garattini; Luigi Naldi
Journal:  Pharmacoeconomics       Date:  2012-11-01       Impact factor: 4.981

Review 6.  The Challenge of Managing Psoriasis: Unmet Medical Needs and Stakeholder Perspectives.

Authors:  Steven R Feldman; Bernard Goffe; Gary Rice; Matthew Mitchell; Mandeep Kaur; Debbie Robertson; Debra Sierka; Jeffrey A Bourret; Tamara S Evans; Alice Gottlieb
Journal:  Am Health Drug Benefits       Date:  2016-12

Review 7.  [Regional variations in healthcare for patients with psoriasis and atopic dermatitis in Germany].

Authors:  M Augustin; C Garbe; S Neitemeier; T Steimle; S Schwarz; J Augustin; R von Kiedrowski; K Hagenström
Journal:  Hautarzt       Date:  2021-11-25       Impact factor: 0.751

Review 8.  Cardiovascular mortality in psoriasis and psoriatic arthritis: epidemiology, pathomechanisms, therapeutic implications, and perspectives.

Authors:  Wolf-Henning Boehncke; Sandra Boehncke
Journal:  Curr Rheumatol Rep       Date:  2012-08       Impact factor: 4.592

9.  Fixed Combination Aerosol Foam Calcipotriene 0.005% (Cal) Plus Betamethasone Dipropionate 0.064% (BD) is More Efficacious than Cal or BD Aerosol Foam Alone for Psoriasis Vulgaris: A Randomized, Double-blind, Multicenter, Three-arm, Phase 2 Study.

Authors:  Mark Lebwohl; Stephen Tyring; Michael Bukhalo; Javier Alonso-Llamazares; Martin Olesen; David Lowson; Paul Yamauchi
Journal:  J Clin Aesthet Dermatol       Date:  2016-02-01

10.  Calcipotriol/Betamethasone Dipropionate Aerosol Foam for Plaque Psoriasis: A Prospective, Observational, Non-Interventional, Single-Center Study of Patient Adherence and Satisfaction in Daily Use.

Authors:  Francisco José Navarro-Triviño; Mario Lozano-Lozano; Ricardo Ruiz-Villaverde
Journal:  Dermatol Pract Concept       Date:  2021-05-20
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.